Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $257,550.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,151 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $50.00, for a total value of $257,550.00. Following the completion of the sale, the director now directly owns 300,695 shares of the company’s stock, valued at $15,034,750. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Stock Down 1.6 %

NASDAQ PDEX traded down $0.77 during mid-day trading on Monday, hitting $48.89. The company’s stock had a trading volume of 36,103 shares, compared to its average volume of 21,554. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The company’s 50 day simple moving average is $39.79 and its 200 day simple moving average is $38.48. Pro-Dex, Inc. has a twelve month low of $16.84 and a twelve month high of $59.60. The firm has a market capitalization of $159.43 million, a price-to-earnings ratio of 24.32 and a beta of 0.68.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. Analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Hedge Funds Weigh In On Pro-Dex

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its holdings in shares of Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares in the last quarter. FMR LLC raised its position in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after buying an additional 1,028 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Pro-Dex by 8.1% during the 4th quarter. Renaissance Technologies LLC now owns 14,740 shares of the medical instruments supplier’s stock valued at $689,000 after acquiring an additional 1,100 shares in the last quarter. Geode Capital Management LLC lifted its stake in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after acquiring an additional 2,296 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Pro-Dex during the 4th quarter worth $202,000. Institutional investors and hedge funds own 15.28% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com cut Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.